Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)
Aliasgar Esmail, Suzette Oelofse, Carl Lombard, et al.
American Journal of Respiratory and Critical Care Medicine (2022) Vol. 205, Iss. 10, pp. 1214-1227
Closed Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
Ruth Goodall, Sarah Meredith, Andrew Nunn, et al.
The Lancet (2022) Vol. 400, Iss. 10366, pp. 1858-1868
Open Access | Times Cited: 80
Update of drug-resistant tuberculosis treatment guidelines: A turning point
Elisa Vanino, Bianca Granozzi, Onno W. Akkerman, et al.
International Journal of Infectious Diseases (2023) Vol. 130, pp. S12-S15
Open Access | Times Cited: 60
Multidrug-resistant tuberculosis
Keertan Dheda, Fuad Mirzayev, Daniela María Cirillo, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 55
Drug-resistant tuberculosis: a persistent global health concern
Maha Farhat, Helen Cox, Marwan Ghanem, et al.
Nature Reviews Microbiology (2024) Vol. 22, Iss. 10, pp. 617-635
Open Access | Times Cited: 53
Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database
Fan Zou, Zhiwei Cui, Siyu Lou, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 36
Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease
Véronique Dartois, Thomas Dick
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 5, pp. 381-403
Open Access | Times Cited: 27
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis
Lorenzo Guglielmetti, Uzma Khan, Gustavo E. Velásquez, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 5, pp. 468-482
Closed Access | Times Cited: 3
The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives
Navisha Dookie, Senamile L. Ngema, Rubeshan Perumal, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 4
Open Access | Times Cited: 38
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea
Jeongha Mok, Myungsun Lee, Deog Kyeom Kim, et al.
The Lancet (2022) Vol. 400, Iss. 10362, pp. 1522-1530
Closed Access | Times Cited: 38
Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis
Lindsay Sonnenkalb, Joshua James Carter, Andrea Spitaleri, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 5, pp. e358-e368
Open Access | Times Cited: 35
Recent advances in the treatment of tuberculosis
Ilaria Motta, Martin J. Boeree, Dumitru Chesov, et al.
Clinical Microbiology and Infection (2023) Vol. 30, Iss. 9, pp. 1107-1114
Open Access | Times Cited: 31
Nine-month, all-oral regimens for rifampin-resistant tuberculosis
Lorenzo Guglielmetti, Uzma Khan, Gustavo E. Velásquez, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 8
Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against Mycobacterium tuberculosis
Md. Mahmudul Islam, Md Shah Alam, Xiaogang Li, et al.
Frontiers in Medicine (2024) Vol. 10
Open Access | Times Cited: 6
The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis
Brett Edwards, Stephen K. Field
Drugs (2022) Vol. 82, Iss. 18, pp. 1695-1715
Open Access | Times Cited: 27
New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians
Jéssica Díaz, Ahmed A. Abulfathi, Lindsey HM te Brake, et al.
Respiration (2022) Vol. 102, Iss. 2, pp. 83-100
Open Access | Times Cited: 22
Prison as a driver of recent transmissions of multidrug-resistant tuberculosis in Callao, Peru: a cross-sectional study
Christian Utpatel, Mariano Sotomayor de Zavaleta, Daniel Rojas‐Bolivar, et al.
The Lancet Regional Health - Americas (2024) Vol. 31, pp. 100674-100674
Open Access | Times Cited: 5
New All-Oral Short-term Regimen for Multidrug-Resistant Tuberculosis: A Semi-randomized Controlled Trial Conducted in China
Jing Wei, Qingfeng Wang, Jun Wang, et al.
Open Forum Infectious Diseases (2025) Vol. 12, Iss. 2
Open Access
Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes
Tom Yates, Daniel Grint
The Lancet Microbe (2025), pp. 101117-101117
Open Access
Update in tuberculosis treatment: a scoping review of current practices
Samuel Campos Lopes, Mariana Marçal, N Fernandes, et al.
Breathe (2025) Vol. 21, Iss. 1, pp. 240232-240232
Open Access
Designing molecular diagnostics for current tuberculosis drug regimens
Sophia B. Georghiou, Margaretha de Vos, Kavindhran Velen, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 11
At long last: short, all-oral regimens for multidrug resistant tuberculosis in the United States
Pranay Sinha, Karen R. Jacobson, C. Robert Horsburgh, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 4
Open Access | Times Cited: 10
Relapse after treatment with standardized all-oral short regimens for rifampicin-resistant tuberculosis (RR-TB): A systematic review and meta-analysis
Ahmad Reza Yosofi, Anita Mesić, Tom Decroo
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases (2024) Vol. 35, pp. 100426-100426
Open Access | Times Cited: 3
Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel
Christoph Lange, Clifton E. Barry, C. Robert Horsburgh
American Journal of Respiratory and Critical Care Medicine (2022) Vol. 205, Iss. 10, pp. 1142-1144
Open Access | Times Cited: 14
Linezolid for Drug-Resistant Tuberculosis
Guy Thwaites, Nhung Viet Nguyen
New England Journal of Medicine (2022) Vol. 387, Iss. 9, pp. 842-843
Closed Access | Times Cited: 14
The Efficacy and Safety of Bedaquiline in the Treatment of Pulmonary Tuberculosis Patients: A Systematic Review and Meta-Analysis
Enyu Tong, Qian Wu, Yi‐Ming Chen, et al.
Antibiotics (2023) Vol. 12, Iss. 9, pp. 1389-1389
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top